Clinical Trials Using Dual ALK/EGFR Inhibitor AP26113

Clinical trials are research studies that involve people. The clinical trials on this list are studying Dual ALK/EGFR Inhibitor AP26113. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-9 of 9
  • Innovative Trial for Understanding the Impact of Targeted Therapies in Neurofibromatosis Type 2, The INTUITT-NF2 Trial

    This phase II trial investigates targeted therapies and how well they work for patients with neurofibromatosis type 2 (NF2)-related tumors. This trial may allow patients with multiple tumor types associated with NF2 to receive new drugs throughout the study. The trial consists of a master study and treatment arms called sub-studies. The master study is intended to enroll patients who will be placed into different sub-studies. The brigatinib sub-study investigates a drug called brigatinib, which acts by blocking the activity of growth pathways in tumors. Because tumors need these signals to grow, brigatinib may slow or reverse the growth of the tumors that develop in people with neurofibromatosis type 2.
    Location: 7 locations

  • Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

    The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got worse, even after, or while taking drugs called ALK inhibitors, or anti-cancer drugs that act on tumors. Some examples of these anti-cancer drugs are: KEYTRUDA® or ALECENSA®).
    Location: 5 locations

  • Brigatinib and Binimetinib in Treating Patients with Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of brigatinib and binimetinib in treating patients with stage IIIB-IV non-small cell lung cancer and a type of gene mutation called a rearrangement in the ALK or ROS1 genes. Brigatinib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Brigatinib before Brain Irradiation Trial for the Treatment of Brain Metastases from ALK+ Lung Cancer, the B3i Trial

    This phase II trial investigates the effect of brigatinib on patients with ALK+ lung cancer that has spread to the brain (brain metastases). Brigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer

    This phase Ib trial studies the side effects and best dose of brigatinib and how well it works with bevacizumab in treating patients with ALK-rearranged non-small cell lung cancer that has spread to nearby tissues or lymph nodes (locally advanced) or other places in the body (metastatic) or has come back (recurrent). Brigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known if brigatinib and bevacizumab will work better in treating patients with ALK-rearranged non-small cell lung cancer.
    Location: 4 locations

  • Brigatinib in Treating Patients with ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

    This phase II trial studies how well brigatinib works in treating patients with ALK and ROS1 gene alterations and solid cancers that have spread to nearby tissue and lymph nodes or other places in the body. Brigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Local Consolidative Therapy and Brigatinib in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer

    This early phase I trial studies the side effects and how well local consolidative therapy (LCT) and brigatinib works in treating patients with non-small cell lung cancer that is stage IV or has come back (recurrent). Giving LCT, such as surgery and / or radiation, after initial treatment may kill any remaining tumor cells. Brigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving LCT and brigatinib may work better in treating patients with non-small cell lung cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

    Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and delivers a dose of chemotherapy directly to the tumor. In this study, participants will be people with non-small-cell lung cancer (NSCLC for short). The main aim of the study is to learn if brigatinib stops the tumors from growing, or if the tumors have shrunk or disappeared, compared to a medicine called alectinib. At the first visit, the study doctor will check who can take part. Participants who can take part will be picked for 1 of 2 treatments by chance: - Brigatinib tablets - Alectinib capsules All participants will take brigatinib or alectinib at about the same time every day. They will continue with treatment throughout the study unless their cancer gets worse, they have side effects from the treatment, they leave the study for certain reasons, or the study is stopped. After stopping treatment, participants will visit the study clinic for a check-up 30 days later.
    Location: See Clinical Trials.gov

  • Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

    This National Cancer Institute (NCI)-NRG ALK Protocol phase II trial studies how well a combination of different biomarker / ALK inhibitors work in treating patients with stage IV ALK positive non-squamous non-small cell lung cancer. Lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether a combination of biomarker / ALK inhibitors or chemotherapy may work better in treating patients with ALK positive non-squamous non-small cell lung cancer.
    Location: 483 locations